Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial

Yeon Hee Park, Rina Hui, Seock-Ah Im, Jin-Hee Ahn, Chiun-Sheng Huang, Min Hwan Kim, Shin-Cheh Chen, Hirofumi Mukai, Masato Takahashi, Hiroji Iwata, Javier Cortés, Heather McArthur, Lajos Pusztai, Sherko Kümmel, Carsten Denkert, Joyce O'Shaughnessy, Nadia Harbeck, Peter A. Fasching, Michael Untch, Fatima Cardoso, Liyi Jia, Francisco Beca, Jaime Mejia, Rebecca Dent, Peter Schmid

Open source

DOI: 10.1016/j.breast.2026.104904
Published: 2026-12
Container: The Breast
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.breast.2026.104904,
  title = {Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial},
  author = {Yeon Hee Park and Rina Hui and Seock-Ah Im and Jin-Hee Ahn and Chiun-Sheng Huang and Min Hwan Kim and Shin-Cheh Chen and Hirofumi Mukai and Masato Takahashi and Hiroji Iwata and Javier Cortés and Heather McArthur and Lajos Pusztai and Sherko Kümmel and Carsten Denkert and Joyce O'Shaughnessy and Nadia Harbeck and Peter A. Fasching and Michael Untch and Fatima Cardoso and Liyi Jia and Francisco Beca and Jaime Mejia and Rebecca Dent and Peter Schmid},
  year = {2026},
  journal = {The Breast},
  doi = {10.1016/j.breast.2026.104904},
  url = {https://doi.org/10.1016/j.breast.2026.104904}
}

RIS

TY  - JOUR
TI  - Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial
AU  - Yeon Hee Park
AU  - Rina Hui
AU  - Seock-Ah Im
AU  - Jin-Hee Ahn
AU  - Chiun-Sheng Huang
AU  - Min Hwan Kim
AU  - Shin-Cheh Chen
AU  - Hirofumi Mukai
AU  - Masato Takahashi
AU  - Hiroji Iwata
AU  - Javier Cortés
AU  - Heather McArthur
AU  - Lajos Pusztai
AU  - Sherko Kümmel
AU  - Carsten Denkert
AU  - Joyce O'Shaughnessy
AU  - Nadia Harbeck
AU  - Peter A. Fasching
AU  - Michael Untch
AU  - Fatima Cardoso
AU  - Liyi Jia
AU  - Francisco Beca
AU  - Jaime Mejia
AU  - Rebecca Dent
AU  - Peter Schmid
PY  - 2026
JO  - The Breast
DO  - 10.1016/j.breast.2026.104904
UR  - https://doi.org/10.1016/j.breast.2026.104904
ER  -

APA

Park, Y. H., Hui, R., Im, S., Ahn, J., Huang, C., Kim, M. H., Chen, S., Mukai, H., Takahashi, M., Iwata, H., Cortés, J., McArthur, H., Pusztai, L., Kümmel, S., Denkert, C., O'Shaughnessy, J., Harbeck, N., Fasching, P. A., Untch, M., Cardoso, F., Jia, L., Beca, F., Mejia, J., Dent, R., & Schmid, P. (2026). Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial. The Breast. https://doi.org/10.1016/j.breast.2026.104904

Source records

crossref · retrieved 2026-09-25T14:58:49.751Z